A Relative Bioavailability Study of Carvedilol 12.5 mg Tablets Under Non-fasting Conditions

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

36 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-10-31

Study Completion Date

2005-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To compare the rate and extent of absorption of carvedilol from a test formulation of Carvedilol 12.5 mg Tablets versus the reference Coreg® 12.5 mg Tablets under fed conditions.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Relative Bioavailability Study of Carvedilol 12.5 mg Tablets Under Fasting Conditions

NCT00864435

Healthy

COMPLETED PHASE1

Fed Study of Carvedilol Tablets 12.5 mg to Coreg® Tablets 12.5 mg

NCT00648622

Healthy

COMPLETED PHASE1

Fasting Study of Carvedilol Tablets 12.5 mg to Coreg® Tablets 12.5 mg

NCT00650416

Healthy

COMPLETED PHASE1

Carvedilol 25 mg in 36 Fasted, Healthy, Adult Subjects

NCT00834795

Healthy

COMPLETED PHASE1

Bioequivalence Study of Carvedilol 12.5mg Tablets Under Fed Conditions

NCT00775619

Healthy

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Study Type: Interventional Study Design: Two-way crossover, randomized, open-label, single-dose, fed, bioequivalence study

Official Title: A Two-Way Crossover, Open-Label, Single Dose, Fed, Bioequivalence Study of Carvedilol 12.5 mg Tablets Versus Coreg® 12.5 mg Tablets in Normal, Healthy, Non-Smoking Male and Female Subjects

Further study details as provided by Actavis Elizabeth LLC:

Primary Outcome Measures:

Rate and Extend of Absorption

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A

Carvedilol 12.5 mg Tablets, single dose

Group Type EXPERIMENTAL

Carvedilol 12.5 mg Tablets, single dose

Intervention Type DRUG

A: Experimental Subjects received Shasun Chemicals and Drugs Ltd. formulated products under fed conditions

B

Coreg® 12.5 mg Tablets , single dose

Group Type ACTIVE_COMPARATOR

Coreg® 12.5 mg Tablets , single dose

Intervention Type DRUG

B: Active comparator Subjects received GlaxoSmithKline, USA formulated products under fed conditions

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Carvedilol 12.5 mg Tablets, single dose

A: Experimental Subjects received Shasun Chemicals and Drugs Ltd. formulated products under fed conditions

Intervention Type DRUG

Coreg® 12.5 mg Tablets , single dose

B: Active comparator Subjects received GlaxoSmithKline, USA formulated products under fed conditions

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Carvedilol Carvedilol

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Non-smoking male or female with a minimum age of 18 years.
2. Body Mass Index (BMI = weight/heigh2) greater than or equal to 18.5 kg/m2 and less than or equal to 29.9 kg/m2
3. Normal findings in the physical examination, 12-lead ECG and vital signs (blood pressure between 106-140/66-90 mmHg, heart rate between 60-99 beats/minute, temperature between 35.8°C and 37.5°C)
4. Negative for drugs of abuse and nicotine.
5. Negative for hepatitis B-surface antigen, hepatitis C and HIV.
6. Female subjects: negative for pregnancy (as evaluated by serum ß-CG test).
7. No clinical laboratory values outside of the acceptable range as defined by BCR, unless the Principal Investigator decides that they are not clinically significant.
8. Female subjects who were surgically sterile for at least 6 months or post-menopausal for at least 1 year, or avoided pregnancy for at least 10 days before the study, during the study and up until 1 month after the end of the study.
9. Availability of the subject for the entire study period and willingness of the subject to adhere to protocol requirements, as evidenced by a signed ICF

Exclusion Criteria

1. Known history of hypersensitivity to carvedilol (e.g. Coreg®) and/or related beta¬blockers such as propranolol (Inderal®, nadolol (Corgard®), labetalol (Trandate®, metoprolol (Lopressor®, Betaloc®, atenolol (Tenormin®, sotalol, timolol, pindolol, or acebutolol.
2. Known history or presence of cardiac, pulmonary, gastrointestinal, endocrine, musculoskeletal, neurological, hematological, liver or kidney disease, unless deemed not clinically significant by the Principal Investigator or Sub-investigator.
3. Presence of any significant physical or organ abnormality.
4. Any history or evidence of psychiatric or psychological disease (including depression) unless deemed not clinically significant by the Principal Investigator or Sub-investigator.
5. Known history of frequent headaches or migraines.
6. Known history of chronic bronchitis or any bronchospastic condition.
7. Any clinically significant illness during the 4 weeks before this study.
8. Known history or presence of food allergies, or any condition known to interfere with the absorption, distribution, metabolism or excretion of drugs.
9. Any history of severe allergic reaction (including drugs, food, insect bites, environmental allergens).
10. Significant or recent history of asthma (after 12 years of age).
11. Any subject with a history of drug abuse.
12. Any subject with a recent (less than 1 year) history of alcohol abuse.
13. Use of any prescription medication within 14 days preceding this study.
14. Use of any over-the-counter (OTC) cough and cold medication containing dextromethorphan within 14 days preceding this study.
15. Use of OTC medication within 7 days preceding this study (except for spermicidal/barrier contraceptive products).
16. Female subjects: use of contraceptives (oral, emergency \[plan B®, transdermal, implant, Mirena® IUD, NuvaRing®) within 30 days before drug administration or a depot injection of progestogen drug (e.g. Depo-Provera® within 1 year before drug administration.
17. Female subjects: evidence of pregnancy or lactation.
18. Any subject who had blood drawn within 56 days preceding this study, during the conduct of any clinical study at a facility other than BCR, or within the lockout period specified by a previous study conducted at BCR.
19. Participated in a clinical trial with an investigational drug within 30 days preceding this study.
20. Any subject who had donated blood within 56 days preceding this study.
21. Any subject who had participated as a plasma donor in a plasmapheresis program within 7 days preceding this study.
22. Intolerance to venipuncture.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes